Wuxi Beta Pharmaceutical Technology

Wuxi Beta Pharmaceutical Technology is a specialized contract research organization (CRO) focused on the synthesis of isotope-labeled compounds for the life sciences industry. The company provides high-quality Carbon-14 (C-14) and Carbon-13 (C-13) labeling services, as well as stable isotope-labeled internal standards for drug metabolism and pharmacokinetics (DMPK) studies. Their expertise extends to the custom synthesis of complex organic molecules, radiolabeled APIs, and metabolites required for regulatory submissions. By supporting pharmaceutical companies in ADME (Absorption, Distribution, Metabolism, and Excretion) studies, Wuxi Beta plays a critical role in the drug development lifecycle. The company operates state-of-the-art radiochemical facilities and maintains a strong reputation for technical precision in chemical synthesis.